Curr Epidemiol Rep by Millman, Alexander J. et al.
Hepatitis C: Review of the Epidemiology, Clinical Care, and 
Continued Challenges in the Direct Acting Antiviral Era
Alexander J. Millman, MD1, Noele P. Nelson, MD PhD1, and Claudia Vellozzi, MD MPH1
1Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 
Centers for Disease Control and Prevention, Atlanta, GA, USA
Abstract
Purpose of Review—This review highlights key studies and recently published data, policies, 
and recommendations related to hepatitis C virus (HCV) epidemiology, transmission, and 
treatment.
Recent Findings—HCV is a leading cause of liver-related deaths, cirrhosis, and hepatocellular 
carcinoma. Since 2011 and accelerating since 2013, new, safe, tolerable, and curative therapies 
have considerably altered clinical and public health frameworks related to the prevention, control 
and clinical management of HCV. Nevertheless, there are several populations in the United States 
that are important to consider because of disparities in HCV prevalence and transmission risk. 
Adults born during 1945–1965 have an estimated anti-HCV antibody prevalence of ~3%, which is 
six times higher than among other adults, are often unaware of their infections, and are at 
increased risk of having HCV-associated morbidity and mortality from decades of chronic 
infection. Since the early 2000s, increasing incidence of acute HCV infections among young, 
white, non-urban people who inject drugs have been reported. Despite promising therapeutic 
advances, significant challenges remain for reducing HCV-associated morbidity and mortality.
Summary—The high burden of HCV and significant health consequences associated with 
chronic infection make HCV a critical public health priority. Advances in HCV treatment have 
created new opportunities for reducing HCV-associated morbidity and mortality. These treatments 
are safe, well-tolerated, and highly effective; however, benefits cannot be realized without a 
significant increase in the number of persons tested for HCV so that all chronically infected 
individuals can be aware of their diagnosis and linked to appropriate clinical care.
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In the United States, hepatitis C virus (HCV) infection is a leading cause of liver-related 
deaths, cirrhosis, and hepatocellular carcinoma [1•, 2•]. HCV was discovered in 1989, but it 
was not until 1992 that the blood supply was screened for HCV; therefore, prior to 1992, 
contaminated blood products had been a primary cause of infection [3–5•]. Currently, HCV 
infection is primarily acquired through percutaneous blood exposure, most commonly 
through injection drug use. In the past, HCV treatments were used infrequently because of 
side effects and modest efficacy; however, since 2011 and then accelerating since 2013, safe, 
tolerable, and curative therapies have considerably altered clinical and public health 
frameworks related to the prevention, control and clinical management of HCV [3•]. Despite 
promising advances, significant challenges remain for reducing HCV-associated morbidity 
and mortality.
Virology, pathogenesis, and clinical course
HCV is an enveloped, positive-sense, single-stranded RNA virus of the Flavivirdae family 
[6–8]. There are 7 major genotypes (6 major genotypes and the recent addition of genotype 
7 found in only a few cases), and as many as 100 subtypes identified by lower-case letters 
[9]. The HCV replication process is error prone, which results in variant viruses known as 
quasispecies [10, 11]. These virologic characteristics and other host genetic factors can 
affect an individual’s disease progression, ability to clear the virus spontaneously, and 
response to treatment [3•].
Acute infection with HCV is frequently asymptomatic; however, 25–30% of those acutely 
infected may have symptoms including fever, jaundice, and abdominal pain [12]. Of adults 
newly infected with HCV, ~15–25% have spontaneous resolution of their infections [13]. 
However, the likelihood of resolution varies by age and virologic and host genetic factors 
[14]. Those who do not resolve their infection develop chronic HCV infection defined as the 
presence of detectable HCV RNA at least six months following the acute infection [13]. 
Those with chronic HCV infection may develop liver fibrosis of varying severity over time, 
and approximately 15–20% of those with chronic infection will develop the most advanced 
form of fibrosis known as cirrhosis [15]. Rates of liver fibrosis progression are influenced by 
host genetic factors, age of infection, co-morbid conditions such as diabetes and certain 
environmental factors such as concurrent alcohol use, but cirrhosis typically develops over a 
couple decades [15]. Those with cirrhosis can become decompensated at rates of 2–4% per 
year or develop hepatocellular carcinoma at rates of 1–7% per year [13]. Additionally, HCV 
can result in multiple manifestations of extrahepatic diseases including diabetes mellitus, 
cryoglobulinemia, non-Hodgkin’s B cell lymphoma, membranoproliferative 
glomerulonephritis, lichen planus, and porphyria cutanea tarda [16]. Finally, persons 
infected with HCV have reported reduced quality of life from symptoms such as fatigue 
[17].
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Bloodborne transmission is the primary mode of HCV transmission [5•]. Unsafe injection 
practices in healthcare settings and recreational injection drug use are particularly important 
for HCV transmission worldwide [5•]. Prior to the screening of blood products for HCV 
beginning in 1992 in the United States, healthcare-associated transmission of HCV occurred 
more frequently [5•]; however, 33 healthcare outbreaks involving more than 239 outbreak-
associated cases were reported to the Centers for Disease Control and Prevention [CDC] 
from 2008–2015 [18]. Vertical transmission can occur in ~6% of infants born to HCV-
infected mothers and transmission may be twice as likely to occur in infants born to 
HCV/HIV co-infected mothers or HCV mono-infected mothers with high viral loads [19–
21]. Sexual transmission is generally inefficient [22]; however, an increasing number of 
cases of sexually transmitted infection have been reported among HIV-infected men who 
have sex with men [MSM] [23, 24]. Finally, HCV transmission has also been reported in the 
setting of non-injection drug use as well as in the setting of unregulated tattoos [25].
Testing and diagnosis
Laboratory diagnosis of chronic HCV infection in the United States currently requires the 
use of two types of tests: immunoglobulin (Ig) G antibody enzyme immunoassays (anti-
HCV) and nucleic acid tests (NAT) [26•]. HCV testing should be initiated with an anti-HCV 
antibody test. Persons without risk factors for HCV and a non-reactive anti-HCV antibody 
require no further evaluation for HCV infection [26•]. Additional testing may be appropriate 
for certain populations with severely compromised immune systems or current risks for 
HCV exposure such as injection drug use or hemodialysis [26•]. A reactive anti-HCV 
antibody requires confirmation with a HCV NAT to determine the presence of HCV RNA 
and current HCV infection [26•]. Persons with a reactive anti-HCV antibody and a positive 
HCV NAT are infected with HCV and should be linked to appropriate HCV medical care 
and treatment [26•]. A person with a reactive anti-HCV antibody and a negative HCV NAT 
does not have HCV infection; this may represent: 1) spontaneous resolution of a previous 
infection, 2) sustained virologic response (SVR) following HCV treatment, or 3) a false 
positive anti-HCV antibody result (although this is rare in populations with risk factors for 
HCV infection) [26•]. If there is a need to distinguish between true or false positivity of the 
anti-HCV antibody result, testing may be done with a second FDA-approved HCV antibody 
assay that is different from the assay used for initial antibody testing [26•].
HCV Testing Recommendations in the United States
HCV testing recommendations in the United States are issued by CDC and the United States 
Preventive Services Task Force (USPSTF) [3–5•, 27•]. The American Association for the 
Study of Liver Disease and Infectious Disease Society of America (AASLD-IDSA) have 
also issued testing recommendations as part of guidance for HCV care and treatment. Table 
1 highlights similarities and differences in the populations currently recommended for HCV 
testing by each organization. Recommendations are based on the presence of known HCV 
transmission risk factors as well as estimated prevalence in certain populations [3–5•, 27•]. 
USPSTF and CDC recommend one time testing with anti-HCV antibody for adults born 
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during 1945–1965 regardless of the presence of known HCV risk factors because prevalence 
is six times higher in that population than among adults born in other years and ~45% of 
people in this birth cohort report no known exposure risk [see Special Populations and 
Disparities Section] [3–5•, 27•, 28•]. This population has been recommended for testing by 
CDC since August 2012 and USPTF (Grade B recommendation) since June 2013 [3–5•, 
27•]. AASLD-IDSA incorporated CDC recommendations into guidance for HCV care and 
treatment [3–5•, 27•]. Finally, all organizations recommend testing for persons of any age 
with the following HCV-related risk factors: current or past injection drug use, receipt of 
blood transfusions prior to 1992, receipt of long-term hemodialysis, and children born to 
HCV-infected mothers [3–5•, 27].
Treatment
Historically, the mainstay of HCV therapy had been interferon and ribavirin-based regimens, 
which were used sparingly because of poorly tolerated side effects and modest efficacy with 
sustained virologic response (SVR) rates of ~50% [29–31]. In 2011, the introduction of two 
NS3/4A protease inhibitors used in combination with interferon-based regimens for chronic 
HCV treatment marked the start of the direct-acting antiviral (DAA) era [29]. Since then 
additional drugs comprising interferon-free DAA regimens with cure rates >90% have 
become available. These drugs target other viral components such as the NS5A protein 
inhibitors and NS5B polymerase inhibitors. These new DAA regimens are all oral, highly 
effective, well-tolerated and typically require only 8–12 weeks of therapy for the majority of 
HCV-infected patients including those with history of previous HCV treatment, 
decompensated cirrhosis, end stage renal disease, HIV/HCV co-infection, and recurrent 
HCV infection post-liver transplantation [32–40•]. Additionally, in June 2016, a new 
treatment regimen effective against all HCV genotypes became available, which has the 
potential to further simplify HCV treatment protocols [41]. In the United States, treatment is 
currently recommended for the vast majority of HCV-infected patients, and the latest 
information on currently available HCV treatment regimens can be accessed through 
AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing and Treating 
Hepatitis C [3•].
Special Populations and Disparities
There are several populations in the United States that are important to consider because of 
disparities in HCV prevalence, transmission risk, and clinical management.
Adults born during 1945–1965
Adults born from 1945–1965, often referred to as “baby boomers,” have an estimated anti-
HCV antibody prevalence of ~3%, which is six times higher than among other adults [4•, 
28•]. Baby boomers are estimated to account for approximately 75–81% of all HCV 
infections in the United States [4•, 28•]. These differences in prevalence are related to 
historical factors such as a higher incidence of HCV infections in the 1970s and 1980s and 
changes in healthcare infection control practices such as injection practices and use of 
universal precautions [4•, 42–44]. Since most baby boomers were likely infected more than 
30 years ago, they are at increased risk of having advanced liver fibrosis (estimated at 27% 
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at time of first diagnosis) and other morbidity and mortality associated with chronic HCV 
infection [45•]. This has been demonstrated by an average annual increase in the HCV 
mortality rate of 0.18 deaths per 100,000 population per year during 1999–2007 and an 
average annual increase in the HCV mortality rate of 0.14 deaths per 100,000 population per 
year during 2003–2013 [1•, 44]. In addition to rising HCV-associated mortality rates, in the 
absence of diagnosis and treatment, disease models project rising morbidity rates estimating 
1.76 million persons with untreated HCV infection will develop cirrhosis, with a peak 
prevalence of 1 million cases occurring from the mid-2020s through the mid-2030s (46).
Although the overall prevalence of HCV infection is higher in adults born during 1945–1965 
than in adults born in other years, prevalence within this population varies by sex, race/
ethnicity, and socioeconomic status. For example, the highest prevalence was found in non-
Hispanic black males (8.1 to 13.9%) [4•, 42], and overall, males had twice the prevalence 
compared with females in the birth cohort [4•, 42]. Additionally, approximately ~30% of 
adults born during 1945–1965 were found to lack health insurance prior to Medicaid 
expansion [4•]. In fact, studies evaluating HCV testing of adults born during 1945–1965 in 
urban emergency departments found HCV antibody positivity rates ranging from 7.3–14.7% 
primarily in socioeconomically disadvantaged populations. [47•, 48].
Disparities, which disproportionately affect people of lower socioeconomic status, create 
challenges for scaling up HCV testing and treatment because of underlying health inequities 
such as differing health care access between groups, and health plan and payer imposed 
restrictions on HCV treatment to control drug cost expenditures [49–53•]. Addressing these 
disparities is critical, because persons born during 1945–1965 are more likely to have 
developed or will develop preventable complications of HCV such as decompensated 
cirrhosis and hepatocellular carcinoma due to many years of chronic HCV infection [46].
People who inject drugs
People who inject drugs (PWIDs) are at increased risk for HCV infection, and the incidence 
of reported acute HCV infections among young people who inject drugs has been increasing 
since the early 2000s [18, 54•, 55•]. The incidence of reported acute HCV in young persons 
observed from 2006–2012 was notable for an annual increase in incidence more than 2 times 
greater in nonurban compared to urban jurisdictions [54•]. Additionally, reported cases were 
predominantly of white race, as likely to be female as male, and to have reported previous 
prescription opioid or powder cocaine use [54•]. Multiple HCV outbreaks among PWIDs in 
nonurban settings including in Appalachia, southern and western states, upstate New York, 
Massachusetts, Wisconsin, Virginia, and Indiana have been reported [54–58]. Notably, in 
2014–2015, Scott County Indiana was the site of a large HIV outbreak fueled by injection 
drug use of extended-release oxymorphone; there were 181 outbreak-related HIV infections 
of whom 167 (92.3%) were co-infected with HCV (58). Furthermore, among the 183 HIV 
negative contacts of case patients tested for HCV in Scott County, 116 (63.4%) were HCV 
positive, which highlights the high HCV prevalence in this population independent of the 
HIV outbreak [58•].
The sociodemographic characteristics of PWIDs, and stigma associated with injection drug 
use, create barriers that impede identifying this population and ensuring access to HCV 
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treatment services. Younger PWIDs, particularly those under the age of 30, may not be 
connected to a “usual source of health care,” which can create challenges for identifying this 
population and linking them to care if infected with HCV [59, 60]. Additionally, although 
current guidelines recommend testing PWIDs for HCV, the stigma associated with this 
behavior may lead some individuals to deny the behavior and therefore miss an opportunity 
for testing [61, 62]. Strategies to increase HCV testing and linkage to care in this population 
have included point-of-care HCV testing at syringe service program sites or other harm 
reduction sites, co-location of addiction treatment and medical services, community 
outreach programs, case management and peer navigators [60, 63•]. Of note, one study at an 
urban safety net hospital found PWIDs under 30 years of age were more likely to become 
engaged with HCV-related care if they were tested in established outpatient primary care 
settings compared with testing in inpatient or emergency departments [60]. Finally, one 
major barrier to treatment access for this population is health plan and payer imposed 
restrictions on HCV treatment. Most Medicaid programs have instituted various substance 
abuse criteria requiring counseling or documented periods of abstinence from drug or 
alcohol use as a prerequisite to authorizing HCV treatment [64•, 65•]. Although concurrent 
drug and alcohol use are not contraindications to HCV treatment on the drug label, the 
health plan and payer restrictions effectively limit access to curative HCV therapy for 
PWID, a population with ongoing transmission risk behaviors [49, 66, 67].
Reinfection is an important consideration for PWIDs who are still injecting drugs. Data on 
reinfection rates following HCV treatment in PWIDs are limited but have been reported to 
range from 1.7 per 100 person-years to 28.8 per 100 person-years [68–72]. Importantly, the 
risk of reinfection after HCV treatment may vary depending on the local prevalence among 
PWID populations such that low prevalence settings have lower rates of reinfection [68]. 
This concept is important because it underpins hypothetical HCV treatment as prevention 
strategies in models used to reduce the HCV burden and transmission risk in PWIDs [73–
75•]. Theoretical dynamic models have shown that scaling up DAA treatment to PWIDs in 
combination with other interventions such as network-based treatment strategies of treating 
injection partners or combining DAA regimens with opioid substitution therapy and high 
coverage needle and syringe programs could significantly reduce HCV prevalence and 
transmission risk [73–75•]. For example, one transmission model determined that if opioid 
substitution therapy and high coverage needle and syringe program covered 40% of PWIDs, 
then annually treating 42 per 1000 PWID over 10 years would halve the prevalence for a 
population with a 60% baseline chronic HCV infection prevalence [73]. These models 
provide useful insight into the efficacy of scaling up HCV treatment in PWIDs in 
combination with other harm reduction services; however, additional empirical evidence is 
needed to validate an HCV treatment as prevention strategy [74].
HIV-infected MSM
Although sexual transmission of HCV is generally inefficient [22], outbreaks of HCV 
related to sexual transmission have been reported in HIV-infected MSM in Europe, 
Australia, Asia, and the United States [23, 24, 76–78•]. Factors associated with incident 
HCV infection among HIV-infected MSM primarily include unprotected receptive anal 
intercourse with multiple partners, antecedent syphilis, gonorrhea or chlamydial infection, 
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history of injection drug use, having sex with concurrent methamphetamine use, and 
douching prior to anal intercourse [24, 79•, 80]. In the United States, two studies with 
national sampling estimated an HCV incidence rate of 0.21–0.51 per 100 person years 
among HIV-infected MSM [79•, 81]. These incidence rates; however, may underestimate the 
true extent of transmission in this population. For example, using mandatory HIV and HCV 
laboratory reporting data from 2000–2010, one study in New York City identified 2,016 
incident cases of HCV among 41,303 HIV-infected MSM without a history of injection drug 
[82]. Hispanics and non-Hispanic blacks had higher HCV diagnosis rates than non-Hispanic 
whites (rate ratio (RR), 1.4 and 1.6 respectively), and MSM diagnosed with syphilis had 
higher HCV diagnosis rates than those without syphilis (RR 2.5) [82]. These findings 
suggest a high risk of sexual transmission of HCV in HIV-infected MSM and underscore the 
importance of testing HIV-infected MSM with ongoing risk factors for HCV at least 
annually to ensure early linkage to HCV care and treatment services [3•].
Similar to PWIDs, reinfection with HCV after curative therapy or spontaneous resolution is 
a concern for this population. Studies evaluating HCV reinfection in HIV-infected MSM 
following HCV treatment and SVR have found reinfection rates ranging from 7.3–15.2 per 
100 persons-years and 2-year cumulative rates of reinfection ranging from 25–33% [83–85]. 
This high reinfection risk highlights the limitations of applying a treatment as prevention 
strategy for HCV in this population without concurrently addressing ongoing sexual or drug 
use risk behaviors.
Infants and Children
Annually, an estimated 40,000 children are born to HCV-infected mothers resulting in up to 
4,000 new perinatally infected children [44, 86, 87]. HCV infection in infants and children is 
often asymptomatic, but pediatric HCV infection can affect overall health status, cognitive 
and behavioral functioning, may result in cirrhosis, hepatocellular carcinoma, or liver 
failure, and results in a 26-fold increased risk of liver-related death [88–92]. Despite the risk 
of worse health outcomes following vertical transmission of HCV, ~25–40% of infants 
infected perinatally resolve their infections spontaneously by 24 months, and spontaneous 
resolution has occurred as late as 7 years after perinatal infection [14]. Approximately 6–
12% of infected older children spontaneously resolve their HCV infections, but some studies 
report rates of spontaneous resolution of ~30% [14, 93]. Infants born to HCV-positive 
mothers should be tested for HCV [3•, 5•, 27•]; however, diagnosing HCV infection in 
infants differs from adults because of the presence of maternal anti-HCV IgG, which affects 
the reliability of anti-HCV antibody results in the first 18 months of life [14]. Therefore, 
testing for anti-HCV antibody should only be performed in children older than 18 months of 
age; those with a reactive anti-HCV antibody test, should then have a serum RNA test to 
diagnose chronic infection [14]. Testing for HCV RNA can occur prior to 18 months of age; 
however, it should not be performed before 2 months of age due to decreased sensitivity of 
HCV RNA PCR tests in the first few weeks of life [14, 94]. Additionally, HCV RNA 
detected early in infancy should be rechecked after 12 months to diagnose chronic infection 
[14]. These diagnostic challenges necessitate close follow up to ensure that HCV infection 
status is determined accurately and appropriate linkage to care can be established.
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In recent years, there have been increases in HCV detection among women of childbearing 
age in the United States, which suggest increased risk for mother-to-child transmission of 
HCV [95•, 96•]. This finding is largely attributable to increases in injection drug use in the 
United States; for example, from 2011–2014, of the pregnant women with anti-HCV 
positivity reported to the Kentucky Department of Health, 38% reported past or current 
injection drug use [95•]. This increased risk for HCV infection among young women, and in 
turn, for mother-to-child transmission of HCV is particularly important because of the 
limited HCV treatment options for infants and children. The recommended FDA-approved 
regimen for children age 3–17 years is PEGylated-interferon-[alpha] with ribavirin, which is 
associated with potential adverse side effects [14]. DAAs are not currently approved for use 
in infants, children younger than 12 years or pregnant women because of lack of evidence 
evaluating safety and efficacy in these populations [3•, 97]. Thus, avoiding adverse 
outcomes due to vertical transmission of HCV necessitates preventing maternal infection or 
treating HCV-infected women of child-bearing-age before pregnancy.
Although children born to HCV-infected mothers should be tested for HCV, there are no 
recommendations to test pregnant women for HCV unless there is a known HCV-risk factor 
[3•, 5•, 27•]. Despite the recommendations for testing these children, a study linking 
surveillance and birth-certificate data found that in a major US city, 84% of children born to 
HCV-positive mothers were not adequately tested for HCV infection [96•]. Similar findings 
of inadequate case-ascertainment of children with HCV infection have also been reported in 
Florida and the United States as a whole [98]. Changes in HCV reporting requirements may 
help to improve identification of HCV-infected infants [95•]; however, identifying and 
testing at-risk mothers is the first necessary step for assessing possible risk of vertical 
transmission and ensuring follow-up of infected newborns. In the absence of a universal 
testing recommendation for pregnant women, it is essential that HCV-risk factors be 
ascertained in prenatal care. Improved communication between primary care providers, 
obstetricians, pediatricians, and patients could improve awareness of risk factors and test 
results to ensure continuity of care for both mother and infant and address substance abuse 
issues [14, 96•, 99]. Finally, providing HCV treatment to HCV-infected mothers, especially 
in the postpartum period, could prevent HCV transmission from mother-to-child in 
subsequent pregnancies [99].
Continued Challenges
Improving Testing, Linkage to Care, and Treatment Access
HCV prevention efforts are important at multiple points of clinical care as patients proceed 
from diagnosis to cure (care cascade). An HCV care cascade can serve as a model for 
identifying opportunities and barriers to improving testing, linkage to care, and treatment 
access [100•, 101•]. This model can also be beneficial because it can be used to evaluate the 
effectiveness of interventions used to improve progression along the cascade.
Testing for HCV is the first and most important step in the care cascade. Despite expansion 
of populations eligible for testing and increased harmonization of testing recommendations 
[3–5•, 27•], an estimated 50% of those with chronic HCV infection have not been tested and 
are unaware of their infection [28•, 100•, 102]. Successful interventions to improve receipt 
Millman et al. Page 8













of HCV antibody and RNA confirmatory testing have included prompts in electronic 
medical records for identifying eligible patients, immediate phlebotomy and expedited HCV 
RNA testing for anti-HCV antibody positive patients, and use of laboratory services that 
perform reflex testing on anti-HCV antibody positive specimens [102–106]. A combination 
of these interventions can be particularly effective. For example, settings with interventions 
such as reflex RNA testing have increased confirmatory RNA testing among persons with 
positive anti-HCV antibody results to >85% [102, 106].
The next step in the cascade is linking HCV-infected persons to a healthcare provider 
capable of providing HCV-specific care and treatment. This can represent a significant 
barrier on the care cascade. A study of 104 healthcare sites in 21 US municipalities from 
2012–2014 found that only 41.4% of anti-HCV antibody positive baby boomers were 
referred to care and that 32.3% attended the first appointment [107]. In addition to “drop 
off” associated with failure to attend a primary care provider (PCP) appointment, referral to 
specialists is another area where patients may fail to progress along the care cascade [102]. 
Interventions such as case management programs and patient navigators have been shown to 
be particularly effective for retaining vulnerable patients in care [63, 102]. Additionally, in 
the era of DAAs and pangenotypic regimens, there are increasing opportunities for PCPs to 
provide HCV-specific care and treatment. Video conferencing to train PCPs in the 
management of HCV-infected persons has been used to successfully scale up HCV treatment 
in underserved settings [108]. Similar success has been found in non-academic, non-
specialist, community health centers in which a training program led by experienced non-
specialist PCPs resulted in an increase in the number of PCPs successfully providing HCV 
treatment to patients with reported SVR rates of 96% [109].
HCV treatment access is the final critical step for completion of the care cascade. Although 
HCV treatment regimens are well tolerated, of short duration, and highly efficacious, the 
high cost of treatment and pre-authorization requirements from third party payers represent 
significant barriers to treatment access [49, 64, 65, 110]. Although treatment of HCV-
infected persons is cost-effective from a societal perspective at the initial list price of 
$83,000–$153,000 per treatment course [110, 111•], even as prices continue to decrease, the 
cost of HCV treatments can create budgetary issues for payers such as Medicaid programs 
on 1–2 year budget cycles [110, 112]. For example, in 2014, as much as 6.7% of state 
Medicaid prescription drug spending was attributable to HCV treatment [96•]. Although 
guidelines for HCV treatment, allowing PCPs to treat HCV, utilization of services such as 
patient navigators and case management can improve HCV treatment access [3•, 102, 108], 
addressing drug pricing and payer restrictions to increase treatment access broadly requires 
health system level intervention [49].
Vaccination
Despite advances in HCV treatments, development of an effective HCV vaccine has proven 
elusive [113, 114]. Vaccine development for HCV has been challenging because of viral 
characteristics including high sequence variability within protein coding regions, active 
evasion of the immune system, and evolution of quasispecies from error-prone replication 
[10, 11, 115]. HCV encodes two surface exposed glycoproteins, E1 and E2 which mediate 
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viral entry [116]. E2 in particular has been a target eliciting a neutralizing antibody 
response; however, HCV’s immune evasion strategies have limited the effectiveness of this 
target [116]. Other HCV envelope vaccine candidates tested in humans include those 
targeting the E1 protein, core-E1E2 DNA, and E1E2 protein [114, 117–120]. A primary T-
cell-based vaccine candidate has also been tested, but failed to induce sufficient response in 
chronically infected patients in a therapeutic vaccination trial [121]. Despite the lack of a 
candidate vaccine, modeling strategies have found that even a low efficacy HCV vaccine 
could halve HCV prevalence and incidence among PWIDs assuming coverage levels 
comparable to that of HBV vaccine (model based on 72% HBV vaccine coverage among 
PWIDs in the United Kingdom in 2013) [122]. Additionally, DAAs do not offer protective 
immunity, which may limit the use of DAA therapy as a treatment as prevention strategy 
[110•]. If DAAs and an effective vaccine could be used concurrently for treatment and 
prevention, re-infection risk would be expected to drop significantly as the number of 
individuals susceptible to HCV infection decreases [110•]. However, until a vaccine is 
developed, prevention strategies aimed at averting incident cases is essential.
Elimination
In April 2016, the National Academy of Sciences released a Phase One Report on 
Eliminating the Public Health Problem of Hepatitis B and C in the United States [123•]. 
Based on the analysis, the committee concluded that control of HCV is feasible in the 
relatively short term, and that while eliminating HCV is feasible, it will require time and 
considerable public will, attention, and resources [123•]. Achieving HCV elimination will 
require sustained efforts and overcoming multiple barriers such as improving public health 
surveillance, increasing the number of persons who are aware of their infection and linked to 
care, and improving access to treatment [123•]. The Cherokee Nation of Eastern Oklahoma 
is the first community in the United States to develop an HCV elimination program [124]. 
The lessons learned from this program will be critical for identifying effective strategies and 
methods for reducing prevalence and incidence in communities throughout the United 
States.
Conclusion
The high burden of HCV and significant health consequences associated with chronic 
infection make HCV a critical public health priority. Advances in HCV treatment have 
created new opportunities for reducing HCV-associated morbidity and mortality. These 
treatments are safe, well-tolerated, and highly effective; however, the benefits cannot be 
realized without a significant increase in the number of persons tested for HCV so that all 
chronically infected individuals can be aware of their diagnosis and linked to appropriate 
clinical care. Prevention and outreach efforts to focus on baby boomers and PWIDs in 
particular will be critical to decreasing prevalence, reducing incidence, and achieving HCV 
elimination.
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Table 1
Hepatitis C Screening Recommendations issued by the United States Preventive Services Task Force 
(USPSTF), Centers for Disease Control and Prevention (CDC), and the American Association for the Study of 
Liver Disease and the Infectious Disease Society of America (AASLD-IDSA)
Risk factor USPSTF CDC AASLD-
IDSA
Adults born during 1945–1965 X X X
Current or past injection drug use X X X
Receipt of blood transfusion before 1992 X X X
Receipt of clotting factor concentrates produced before 1987 X X
Organ transplant before July 1992 X X
Long-term hemodialysis X X X
Children born to HCV-positive women X X X
Incarceration X X
Intranasal drug use X * X
Other non-injecting illegal drug use *
Receipt of an unregulated tattoo X * X
Other percutaneous exposures X




Persistently abnormal alanine aminotransferase (ALT) X X
Unexplained chronic liver disease and chronic hepatitis X
Solid organ donors (deceased and living) X
Persons with a history of multiple sex partners or sexually transmitted diseases *
Long-term steady sex partners of HCV-positive persons *
Recipients of transplanted tissue (e.g. corneal, musculoskeletal, skin, ova, sperm) *
Adapted from Guidelines and Guidance from United States Preventive Services Task Force (USPSTF), Centers for Disease Control and Prevention 
(CDC), and the American Association for the Study of Liver Disease and the Infectious Disease Society of America (AASLD-IDSA)
Abbreviations: Hepatitis C Virus (HCV); United States Preventive Services Task Force (USPSTF); Centers for Disease Control and Prevention 
(CDC), and the American Association for the Study of Liver Disease and the Infectious Disease Society of America (AASLD-IDSA); Alanine 
aminotransferase (ALT)
*
Mentioned in guidelines but described as of uncertain need
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